Product image of Granisetron Torrent Pharma (Uk) (Granisetron) supplied by GNH India

Granisetron Torrent Pharma (Uk)

Active Ingredient:
Granisetron
Origin:
EU

Granisetron Torrent Pharma (Uk) (Granisetron)

Granisetron Torrent Pharma (UK) is a prescription medication whose active ingredient is granisetron. It is supplied in oral dosage form, with strength not specified in the available data, and is marketed in the European Union. Granisetron belongs to the 5‑HT3 receptor antagonist class and is used as an antiemetic to help prevent nausea and vomiting associated with chemotherapy or surgery or other medically induced triggers.

Manufacturer / TM Owner

Torrent Pharma (Uk) Ltd.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Granisetron Torrent Pharma is indicated for the prevention of nausea and vomiting in several clinical settings.

  • Prevention of chemotherapy‑induced nausea and vomiting (CINV).
  • Prevention of postoperative nausea and vomiting (PONV).
  • Use as part of antiemetic regimens for radiotherapy‑related nausea.
  • Adjunct therapy for patients receiving highly emetogenic treatments.
  • Management of nausea associated with diagnostic procedures that use contrast agents.
  • Supportive care for nausea in patients with gastrointestinal disorders when other treatments are insufficient.

Side Effects

The safety profile of granisetron includes both common and less frequent adverse effects.

Common

  • Headache.
  • Constipation.
  • Diarrhea.
  • Fatigue.
  • Dizziness.

Serious

  • Allergic reactions such as rash or itching.
  • Severe cardiac arrhythmias.
  • QT interval prolongation.
  • Anaphylaxis (rare).
  • Serotonin syndrome when combined with serotonergic agents.

Precautions & Warnings

Before initiating therapy with Granisetron Torrent Pharma, clinicians should consider several precautionary factors.

  • Assess patient history for cardiac conduction abnormalities.
  • Evaluate for known hypersensitivity to granisetron or other 5‑HT3 antagonists.
  • Use caution in patients receiving other drugs that affect QT interval.
  • Monitor renal or hepatic impairment, as dose adjustment may be required.
  • Consider pregnancy and breastfeeding status; safety data are limited.
  • Review concomitant use of serotonergic medications.

Avoid Interactions

Granisetron may interact with other medications, influencing efficacy or safety.

Avoid

  • Drugs that significantly prolong the QT interval (e.g., certain antiarrhythmics, antipsychotics).
  • Concurrent use with other 5‑HT3 antagonists.

Use with caution

  • Antidepressants that increase serotonin levels (SSRIs, SNRIs, MAO inhibitors).
  • Antifungal agents such as ketoconazole that affect metabolism.
  • Anesthetics or opioids that can also cause nausea.

Frequently Asked Questions

Granisetron Torrent Pharma is a prescription oral medication that contains the active ingredient granisetron, a selective 5‑HT3 receptor antagonist used as an antiemetic.

It is commonly prescribed to prevent nausea and vomiting caused by chemotherapy, postoperative recovery, and radiotherapy, as well as other medically induced nausea.

Granisetron blocks serotonin 5‑HT3 receptors in the central nervous system and gastrointestinal tract, preventing the signal cascade that triggers nausea and vomiting.

No, Granisetron Torrent Pharma is a prescription‑only medication and must be prescribed by a qualified healthcare professional.

Granisetron can be combined with other anti‑nausea agents, but clinicians should review potential drug interactions, especially with medications that affect the QT interval or serotonin levels.

Common side effects include headache, constipation, diarrhea, fatigue, and dizziness.

Serious reactions, although rare, may include allergic skin reactions, severe cardiac arrhythmias, QT prolongation, anaphylaxis, and serotonin syndrome when used with serotonergic drugs.

Patients with known cardiac conduction abnormalities or those taking other QT‑prolonging drugs should be evaluated carefully before starting granisetron.

Safety data for granisetron in pregnancy and lactation are limited; it should be used only if the potential benefit justifies the potential risk.

The medication is taken orally as directed by a healthcare provider, typically before the start of chemotherapy or surgery.

If a dose is missed, the patient should follow the prescribing clinician’s instructions, which usually involve taking the missed dose as soon as remembered unless the next scheduled dose is near.

Additional information can be obtained from the prescribing information, the European Medicines Agency (EMA) database, or by consulting a pharmacist or healthcare professional.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Granisetron

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT